Development of anti-5T4 antibody-drug conjugates, ZVO5-ADCs for targeted cancer therapy in different type of cancers

被引：0
|
作者：
Li, Zhaohui
Xie, Zhangming
Zhang, Qian
Fang, Jie
Wu, Liqin
Fang, Hedi
Zhang, Hong
Zhu, Tong
Chen, Gang
Miao, David
Cao, Sheldon
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-1214
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1214
引用
收藏
页数：3
相关论文
共 22 条
  • [21] Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer (vol 14, pg 465, 2019)
    Wan, Y. Louise
    Sapra, Puja
    Bolton, James
    Chua, Jia Xin
    Durrant, Lindy G.
    Stern, Peter L.
    TARGETED ONCOLOGY, 2019, 14 (06) : 769 - 769
  • [22] Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index
    Schmitt, Saskia
    Mai, Isabelle
    Machui, Paul
    Herterich, Sarah
    Hauswald, Danila
    Ochtrop, Philipp
    Cyprys, Philipp
    Kozlowska, Izabela
    Kitowski, Annabel
    Gerlach, Marcus
    Marcq, Olivier
    Trail, Pamela A.
    Schumacher, Dominik
    Kasper, Marc-Andre
    Fingerle-Rowson, Guenter
    Hock, Bjorn
    Helma-Smets, Jonas
    Vogl, Annette M.
    CANCER RESEARCH, 2024, 84 (06)
123